This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
Augusta University Georgia Cancer Center
Augusta, Georgia, United States
Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed
Dose-limiting toxicity of grade 3 or higher using CTCAE 5
Time frame: 4 weeks or 28 days assessment.
Assess objective response rate (RR)
RR measured by Tumor response evaluation with RECIST
Time frame: To be measured through study completion; an average of 1 year.
Progression-free survival (PFS)
PFS measured from the time of study treatment to the date of progression.
Time frame: To be measured through study completion; an average of 1 year.
Overall survival (OS).
Measured from the time of start of treatment to time of death or time of last assessment.
Time frame: OS measured through study completion, and an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.